1. Parvizi J, Della Valle CJ. AAOS Clinical Practice
Guideline: diagnosis and treatment of periprosthetic
joint infections of the hip and knee. JAAOS-Journal
of the American Academy of Orthopaedic Surgeons.
2010; 18(12):771-2.
2. Parvizi J, Erkocak OF, Della Valle CJ. Culture-negative
periprosthetic joint infection. JBJS. 2014; 96(5):430-6.
3. Parvizi J, Tan TL, Goswami K, Higuera C, Della Valle C,
Chen AF, et al. The 2018 definition of periprosthetic
hip and knee infection: an evidence-based and
validated criteria. The Journal of arthroplasty. 2018;
33(5):1309-14.
4. Shohat N, Tan TL, Della Valle CJ, Calkins TE, George
J, Higuera C, et al. Development and validation
of an evidence-based algorithm for diagnosing
periprosthetic joint infection. The Journal of
arthroplasty. 2019; 34(11):2730-6.
5. Alijanipour P, Bakhshi H, Parvizi J. Diagnosis of
periprosthetic joint infection: the threshold for
serological markers. Clinical Orthopaedics and
Related Research®. 2013; 471(10):3186-95.
6. Tarabichi M, Shohat N, Goswami K, Parvizi J. Can
next generation sequencing play a role in detecting
pathogens in synovial fluid? The bone & joint journal.
2018; 100(2):127-33.
7. AALTO K, Ö STERMAN K, PELToLA HE, RÄ SÄ NEN
J. Changes in erythrocyte sedimentation rate and
C-reactive protein after total hip arthroplasty.
Clinical Orthopaedics and Related Research®. 1984;
184:118-20
8. Ghanem E, Antoci Jr V, Pulido L, Joshi A, Hozack W,
Parvizi J. The use of receiver operating characteristics
analysis in determining erythrocyte sedimentation
rate and C-reactive protein levels in diagnosing
periprosthetic infection prior to revision total hip
arthroplasty. International Journal of Infectious
Diseases. 2009; 13(6):e444-9.
9. Saleh A, George J, Faour M, Klika AK, Higuera CA.
Serum biomarkers in periprosthetic joint infections.
Bone & joint research. 2018; 7(1):85-93.
10. Paul HY, Cross MB, Moric M, Levine BR, Sporer SM,
Paprosky WG, et al. Do serologic and synovial tests
help diagnose infection in revision hip arthroplasty
with metal-on-metal bearings or corrosion? Clinical
Orthopaedics and Related Research®. 2015; 473(2):
498-505.
11. Kwon YM, Antoci Jr V, Leone WA, Tsai TY, Dimitriou
D, Liow MH. Utility of serum inflammatory and
synovial fluid counts in the diagnosis of infection in
taper corrosion of dual taper modular stems. The
Journal of Arthroplasty. 2016; 31(9):1997-2003.
12. McArthur BA, Abdel MP, Taunton MJ, Osmon DR,
Hanssen AD. Seronegative infections in hip and knee
arthroplasty: periprosthetic infections with normal
erythrocyte sedimentation rate and C-reactive
protein level. The bone & joint journal. 2015;
97(7):939-44.
13. Shahi A, Deirmengian C, Higuera C, Chen A, Restrepo
C, Zmistowski B, et al. Premature therapeutic
antimicrobial treatments can compromise the
diagnosis of late periprosthetic joint infection.
Clinical Orthopaedics and Related Research®. 2015;
473(7):2244-9.
14. Vijayan AL, Ravindran S, Saikant R, Lakshmi S, Kartik
R. Procalcitonin: a promising diagnostic marker for
sepsis and antibiotic therapy. Journal of intensive
care. 2017; 5(1):1-7.
15. Assicot M, Bohuon C, Gendrel D, Raymond J, Carsin H,
Guilbaud J. High serum procalcitonin concentrations
in patients with sepsis and infection. The Lancet.
1993; 341(8844):515-8.
16. Hunziker S, Hügle T, Schuchardt K, Groeschl I,
Schuetz P, Mueller B, et al. The value of serum
procalcitonin level for differentiation of infectious
from noninfectious causes of fever after orthopaedic
surgery. JBJS. 2010; 92(1):138-48.
17. Becker KL, Snider R, Nylen ES. Procalcitonin in
sepsis and systemic inflammation: a harmful
biomarker and a therapeutic target. British journal
of pharmacology. 2010; 159(2):253-64.
18. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J.
Serum procalcitonin and C-reactive protein levels as
markers of bacterial infection: a systematic review
and meta-analysis. Clinical infectious diseases. 2004;
39(2):206-17.
19. Battistelli S, Fortina M, Carta S, Guerranti R, Nobile F,
Ferrata P. Serum C-reactive protein and procalcitonin
kinetics in patients undergoing elective total hip
arthroplasty. BioMed Research International. 2014;
2014.
20. Xie K, Qu X, Yan M. Procalcitonin and α-defensin
for diagnosis of periprosthetic joint infections. The
Journal of Arthroplasty. 2017; 32(4):1387-94.
21. Hugle T, Schuetz P, Mueller B, Laifer G, Tyndall
A, Regenass S, et al. Serum procalcitonin for
discrimination between septic and non-septic
arthritis. Clinical & Experimental Rheumatology.
2008; 26(3):453.
22. Drago L, Vassena C, Dozio E, Corsi MM, De Vecchi E,
Mattina R, et al. Procalcitonin, C-reactive protein,
interleukin-6, and soluble intercellular adhesion
molecule-1 as markers of postoperative orthopaedic
joint prosthesis infections. International Journal
of Immunopathology and Pharmacology. 2011;
24(2):433-40.
23. Glehr M, Friesenbichler J, Hofmann G, Bernhardt GA,
Zacherl M, Avian A, et al. Novel biomarkers to detect
infection in revision hip and knee arthroplasties.
Clinical Orthopaedics and Related Research®. 2013;
471(8):2621-8.
24. Tanaka T, Narazaki M, Kishimoto T. IL-6 in
inflammation, immunity, and disease. Cold Spring
Harbor perspectives in biology. 2014; 6(10):a016295.
25. Elgeidi A, Abou Elkhier N, Rakha S. Interleukin-6
and other inflammatory markers in diagnosis
of periprosthetic joint infection. International
orthopaedics. 2014; 38(12):2591-5.
26. Bottner F, Wegner A, Winkelmann W, Becker K, Erren
M, Götze C. Interleukin-6, procalcitonin and TNF-α:
markers of peri-prosthetic infection following total
joint replacement. The Journal of bone and joint
surgery. British volume. 2007; 89(1):94-9.
27. Randau TM, Friedrich MJ, Wimmer MD, Reichert
B, Kuberra D, Stoffel-Wagner B, et al. Interleukin-6
in serum and in synovial fluid enhances the
differentiation between periprosthetic joint infection
and aseptic loosening. PloS one. 2014; 9(2):e89045.
28. Moresco RN, Vargas LC, Voegeli CF, Santos RC. Ddimer
and its relationship to fibrinogen/fibrin
degradation products (FDPs) in disorders associated
with activation of coagulation or fibrinolytic
systems. Journal of clinical laboratory analysis.
2003; 17(3):77-9.
29. Shahi A, Kheir MM, Tarabichi M, Hosseinzadeh HR,
Tan TL, Parvizi J. Serum D-dimer test is promising
for the diagnosis of periprosthetic joint infection and
timing of reimplantation. JBJS. 2017; 99(17):1419-27.
30. Pulivarthi S, Gurram MK. Effectiveness of d-dimer as
a screening test for venous thromboembolism: an
update. North American Journal of Medical Sciences.
2014; 6(10):491.
31. Lippi G, Bonfanti L, Saccenti C, Cervellin G. Causes
of elevated D-dimer in patients admitted to a large
urban emergency department. European journal of
internal medicine. 2014; 25(1):45-8.
32. Amaral A, Opal SM, Vincent JL. Coagulation in sepsis.
Intensive care medicine. 2004; 30(6):1032-40.
33. Rodelo JR, De la Rosa G, Valencia ML, Ospina S,
Arango CM, Gómez CI, et al. D-dimer is a significant
prognostic factor in patients with suspected infection
and sepsis. The American journal of emergency
medicine. 2012; 30(9):1991-9.
34. Lee YS, Lee YK, Han SB, Nam CH, Parvizi J, Koo KH.
Natural progress of D-dimer following total joint
arthroplasty: a baseline for the diagnosis of the
early postoperative infection. Journal of orthopaedic
surgery and research. 2018; 13(1):36.
35. Gall L, Davenport R, Brohi K. Effect of early tranexamic
acid on the coagulation system in patients with
suspected traumatic haemorrhage: a prospective
cohort study. The Lancet. 2016; 387:S46.
36. Berner R, Fürll B, Stelter F, Dröse J, Müller HP,
Schütt C. Elevated levels of lipopolysaccharidebinding
protein and soluble CD14 in plasma in
neonatal early-onset sepsis. Clinical and Diagnostic
Laboratory Immunology. 2002; 9(2):440-5.
37. Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14
subtype presepsin (sCD14-ST) and lipopolysaccharide
binding protein (LBP) in neonatal sepsis: new clinical
and analytical perspectives for two old biomarkers.
The Journal of Maternal-Fetal & Neonatal Medicine.
2011; 24(sup2):12-4.
38. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ,
Mathison JC. CD14, a receptor for complexes of
lipopolysaccharide (LPS) and LPS binding protein.
Science. 1990; 249(4975):1431-3.
39. Wan Y, Freeswick PD, Khemlani LS, Kispert PH, Wang
SC, Su GL, et al. Role of lipopolysaccharide (LPS),
interleukin-1, interleukin-6, tumor necrosis factor,
and dexamethasone in regulation of LPS-binding
protein expression in normal hepatocytes and
hepatocytes from LPS-treated rats. Infection and
immunity. 1995; 63(7):2435-42.
40. Schumann RR, Flaggs GW, Gray PW, Wright SD,
Mathison JC, Tobias PS, et al. Structure and function
of lipopolysaccharide binding protein. Science. 1990;
249(4975):1429-31.
41. Friedrich MJ, Randau TM, Wimmer MD, Reichert B,
Kuberra D, Stoffel-Wagner B, et al. Lipopolysaccharidebinding
protein: a valuable biomarker in the
differentiation between periprosthetic joint infection
and aseptic loosening? International orthopaedics.
2014; 38(10):2201-7.
42. Desmedt S, Desmedt V, Delanghe JR, Speeckaert
R, Speeckaert MM. The intriguing role of soluble
urokinase receptor in inflammatory diseases.
Critical Reviews in Clinical Laboratory Sciences.
2017; 54(2):117-33.
43. Ni W, Han Y, Zhao J, Cui J, Wang K, Wang R, et al.
Serum soluble urokinase-type plasminogen activator
receptor as a biological marker of bacterial infection
in adults: a systematic review and meta-analysis.
Scientific reports. 2016; 6(1):1-8.
44. Slot O, Brünner N, Locht H, Oxholm P, Stephens RW.
Soluble urokinase plasminogen activator receptor
in plasma of patients with inflammatory rheumatic
disorders: increased concentrations in rheumatoid
arthritis. Annals of the Rheumatic Diseases. 1999;
58(8):488-92.
45. de Bock CE, Wang Y. Clinical significance of
urokinase‐type plasminogen activator receptor
(uPAR) expression in cancer. Medicinal research
reviews. 2004; 24(1):13-39.
46. Blasi F, Cubellis MV, Masucci MT, Møller LB, Olson
DP, Pedersen N ,et al. The urokinase receptor and
regulation of cell surface plasminogen activation.
Cell Differentiation and Development. 1990;
32(3):247-53.
47. Bifulco K, Longanesi‐Cattani I, Gala M, Di Carluccio
G, Masucci MT, Pavone V, et al. The soluble form of
urokinase receptor promotes angiogenesis through
its Ser88‐Arg‐Ser‐Arg‐Tyr92 chemotactic sequence.
Journal of Thrombosis and Haemostasis. 2010;
8(12):2789-99.
48. Koch A, Voigt S, Kruschinski C, Sanson E, Dückers
H, Horn A, et al. Circulating soluble urokinase
plasminogen activator receptor is stably elevated
during the first week of treatment in the intensive
care unit and predicts mortality in critically ill
patients. Critical care. 2011; 15(1):R63.
49. Huttunen R, Syrjänen J, Vuento R, Hurme M, Huhtala
H, Laine J, et al. Plasma level of soluble urokinasetype
plasminogen activator receptor as a predictor
of disease severity and case fatality in patients with
bacteraemia: a prospective cohort study. Journal of
internal medicine. 2011; 270(1):32-40.
50. Galliera E, Drago L, Marazzi MG, Romano C, Vassena C,
Romanelli MM. Soluble urokinase-type plasminogen
activator receptor (suPAR) as new biomarker of
the prosthetic joint infection: correlation with
inflammatory cytokines. Clinica Chimica Acta. 2015;
441:23-8.
51. Landmann R, Knopf HP, Link S, Sansano S, Schumann
R, Zimmerli W. Human monocyte CD14 is upregulated
by lipopolysaccharide. Infection and immunity.
1996; 64(5):1762-9.
52. Hailman E, Vasselon T, Kelley M, Busse LA, Hu MC,
Lichenstein HS, et al. Stimulation of macrophages
and neutrophils by complexes of lipopolysaccharide
and soluble CD14. The Journal of Immunology. 1996;
156(11):4384-90.
53. Marazzi MG, Randelli F, Brioschi M, Drago L, Romanò
CL, Banfi G, et al. Presepsin: a potential biomarker
of PJI? A comparative analysis with known and
new infection biomarkers. International Journal
of Immunopathology and Pharmacology. 2018;
31:0394632017749356.
54. Staunton DE, Marlin SD, Stratowa C, Dustin
ML, Springer TA. Primary structure of ICAM-1
demonstrates interaction between members of the
immunoglobulin and integrin supergene families.
Cell. 1988; 52(6):925-33.
55. Frank PG, Lisanti MP. ICAM-1: role in inflammation
and in the regulation of vascular permeability.
American Journal of Physiology-Heart and Circulatory
Physiology. 2008; 295(3):H926-7.
56. Ledebur HC, Parks TP. Transcriptional Regulation
of the Intercellular Adhesion Molecule-1 Gene by
Inflammatory Cytokines in Human Endothelial Cells
ESSENTIAL ROLES OF A VARIANT NF-κB SITE AND
p65 HOMODIMERS. Journal of Biological Chemistry.
1995; 270(2):933-43.
57. Worthington T, Dunlop D, Casey A, Lambert P, Luscombe
J, Elliott T. Serum procalcitonin, interleukin-6, soluble
intercellular adhesin molecule-1 and IgG to shortchain
exocellular lipoteichoic acid as predictors of infection
in total joint prosthesis revision. British journal of
biomedical science. 2010; 67(2):71-6.
58. Shahi A, Parvizi J. The role of biomarkers in the
diagnosis of periprosthetic joint infection. EFORT
Open Rev. 2016;1(7):275-8.
59. Frangiamore SJ, Saleh A, Grosso MJ, Kovac MF, Zhang
X, Daly TM, et al. Neer Award 2015: analysis of
cytokine profiles in the diagnosis of periprosthetic
joint infections of the shoulder. Journal of shoulder
and elbow surgery. 2017; 26(2):186-96.
60. Deirmengian C, Hallab N, Tarabishy A, Della Valle C,
Jacobs JJ, Lonner J, et al. Synovial fluid biomarkers
for periprosthetic infection. Clinical Orthopaedics
and Related Research®. 2010; 468(8):2017-23.
61. Xie K, Dai K, Qu X, Yan M. Serum and synovial fluid
interleukin-6 for the diagnosis of periprosthetic
joint infection. Scientific reports. 2017; 7(1):1-1.
62. Parvizi J, Jacovides C, Antoci V, Ghanem E. Diagnosis
of periprosthetic joint infection: the utility of a
simple yet unappreciated enzyme. JBJS. 2011;
93(24):2242-8.
63. Aggarwal VK, Tischler E, Ghanem E, Parvizi J.
Leukocyte esterase from synovial fluid aspirate: a
technical note. The Journal of arthroplasty. 2013;
28(1):193-5.
64. Li R, Li X, Yu B, Li X, Song X, Li H, et al. Comparison
of leukocyte esterase testing of synovial fluid with
synovial histology for the diagnosis of periprosthetic
joint infection. Medical Science Monitor:
International Medical Journal of Experimental and
Clinical Research. 2017; 23:4440.
65. Wang C, Li R, Wang Q, Duan J, Wang C. Leukocyte esterase
as a biomarker in the diagnosis of periprosthetic joint
infection. Medical science monitor: international
medical journal of experimental and clinical research.
2017; 23:353.
66. Ganz T. Defensins: antimicrobial peptides of innate
immunity. Nature reviews immunology. 2003;
3(9):710-20.
67. De Smet K, Contreras R. Human antimicrobial
peptides: defensins, cathelicidins and histatins.
Biotechnology letters. 2005; 27(18):1337-47.
68. Ding J, Chou YY, Chang TL. Defensins in viral infections.
Journal of innate immunity. 2009; 1(5):413-20.
69. Bonanzinga T, Zahar A, Dütsch M, Lausmann C,
Kendoff D, Gehrke T. How reliable is the alpha-defensin
immunoassay test for diagnosing periprosthetic joint
infection? A prospective study. Clinical Orthopaedics
and Related Research®. 2017; 475(2):408-15.
70. Deirmengian C, Kardos K, Kilmartin P, Cameron
A, Schiller K, Parvizi J. Combined measurement of
synovial fluid α-Defensin and C-reactive protein
levels: highly accurate for diagnosing periprosthetic
joint infection. JBJS. 2014; 96(17):1439-45.
71. Bingham J, Clarke H, Spangehl M, Schwartz A,
Beauchamp C, Goldberg B. The alpha defensin-1
biomarker assay can be used to evaluate the
potentially infected total joint arthroplasty. Clinical
Orthopaedics and Related Research®. 2014;
472(12):4006-9.
72. Shahi A, Parvizi J, Kazarian GS, Higuera C, Frangiamore
S, Bingham J, et al. The alpha-defensin test for
periprosthetic joint infections is not affected by prior
antibiotic administration. Clinical Orthopaedics and
Related Research®. 2016; 474(7):1610-5.
73. Deirmengian C, Kardos K, Kilmartin P, Gulati S,
Citrano P, Booth RE. The alpha-defensin test for
periprosthetic joint infection responds to a wide
spectrum of organisms. Clinical Orthopaedics and
Related Research®. 2015; 473(7):2229-35.
74. Partridge DG, Gordon A, Townsend R. False-positive
synovial fluid alpha-defensin test in a patient with
acute gout affecting a prosthetic knee. European
Journal of Orthopaedic Surgery & Traumatology.
2017; 27(4):549-51.
75. Parvizi J, McKenzie JC, Cashman JP. Diagnosis
of periprosthetic joint infection using synovial
C-reactive protein. The Journal of arthroplasty. 2012;
27(8):12-6.
76. Ettinger M, Calliess T, Kielstein JT, Sibai J, Brückner
T, Lichtinghagen R, et al. Circulating biomarkers
for discrimination between aseptic joint failure,
low-grade infection, and high-grade septic failure.
Clinical Infectious Diseases. 2015; 61(3):332-41.
77. Vasselon T, Detmers PA. Toll receptors: a central
element in innate immune responses. Infection and
immunity. 2002; 70(3):1033-41.
78. Yoshimura A, Lien E, Ingalls RR, Tuomanen E,
Dziarski R, Golenbock D. Cutting edge: recognition of
Gram-positive bacterial cell wall components by the
innate immune system occurs via Toll-like receptor
2. The Journal of Immunology. 1999; 163(1):1-5.
79. Brightbill HD, Libraty DH, Krutzik SR, Yang RB, Belisle
JT, Bleharski JR, et al. Host defense mechanisms
triggered by microbial lipoproteins through toll-like
receptors. Science. 1999; 285(5428):732-6.
80. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H,
Ogawa T,et al. Differential roles of TLR2 and TLR4
in recognition of gram-negative and gram-positive
bacterial cell wall components. Immunity. 1999;
11(4):443-51.
81. Cipriano C, Maiti A, Hale G, Jiranek W. The
host response: Toll-like receptor expression in
periprosthetic tissues as a biomarker for deep joint
infection. JBJS. 2014; 96(20):1692-8.
82. Namdari S, Nicholson T, Abboud J, Lazarus M, Ramsey
ML, Williams G, et al. Comparative study of cultures
and next-generation sequencing in the diagnosis
of shoulder prosthetic joint infections. Journal of
Shoulder and Elbow Surgery. 2019; 28(1):1-8.
)